Welcome to the THALOMID REMS® program

Important information about THALOMID® (thalidomide) and the THALOMID Risk Evaluation
and Mitigation Strategy (REMS) program

  • THALOMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with THALOMID provided adequate precautions are taken to avoid pregnancy

  • To avoid embryo-fetal exposure, THALOMID is only available under a restricted distribution program called "THALOMID REMS®"

  • Only prescribers and pharmacies certified by the THALOMID REMS® program can prescribe and dispense THALOMID to patients who are enrolled and meet all the conditions of the THALOMID REMS® program

The goals of the THALOMID risk evaluation and mitigation strategy are as follows:

  1. To prevent the risk of embryo-fetal exposure to THALOMID

  2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for THALOMID

For additional information about the THALOMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Download the
Celgene REMS mobile app
for CelgeneRiskManagement.com
to your iPad here: